NCT04385368: A reported trial by AstraZeneca
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04385368 |
|---|---|
| Title | A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 17, 2020 |
| Completion date | Aug. 31, 2023 |
| Required reporting date | Aug. 30, 2024, midnight |
| Actual reporting date | Aug. 7, 2024 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |